Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MBS ETF (MBB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

iShares MBS ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares MBS ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MBS ETF trades at $93.22, while Zimmer Biomet Holdings Inc trades at $95.27 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while iShares MBS ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.

MBBZBH
52-Week High
$96.91$107.71
52-Week Low
$92.72$79.58
Market Cap
$18.55B
Sector
Health
Enterprise Value
$25.61B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MBS ETF

MBB trades at $93.28, up 0.38% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent corporate actions include dividend payments of $0.33-$0.34 per share in mid-2026. Focus Financial Network increased its stake by 13.8% in the latest quarter, holding 49,056 shares as of its most recent SEC filing.

The outlook remains cautious due to bearish technical indicators and limited fundamental data availability. Key risks include market volatility and reliance on institutional interest. Investment opportunities hinge on dividend income and potential institutional accumulation, but the lack of current financial metrics warrants careful evaluation.

Zimmer Biomet Holdings Inc

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.

Returns comparison

Trailing returns across standard periods

About iShares MBS ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.

Read more on MBB

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH